RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer

Expert Opin Ther Targets. 2020 Jan;24(1):1-5. doi: 10.1080/14728222.2020.1709824. Epub 2019 Dec 27.

Authors

My-My Huynh¹, Aarthi Jayanthan¹, Mary Rose Pambid¹, Gerrit Los², Sandra E Dunn^{1

2}

Affiliations

¹ Phoenix Molecular Designs, Vancouver, British Columbia, Canada.
² Phoenix Molecular Designs, San Diego, CA, USA.

PMID: 31875730
DOI: 10.1080/14728222.2020.1709824

No abstract available

Keywords: Kinase inhibitors; RSK2; targeted therapy; triple-negative breast cancer (TNBC).

Publication types

Editorial

MeSH terms

Animals
Female
Humans
Molecular Targeted Therapy*
Protein Kinase Inhibitors / pharmacology
Ribosomal Protein S6 Kinases, 90-kDa / antagonists & inhibitors*
Ribosomal Protein S6 Kinases, 90-kDa / metabolism
Triple Negative Breast Neoplasms / drug therapy*
Triple Negative Breast Neoplasms / pathology

Substances

Protein Kinase Inhibitors
Ribosomal Protein S6 Kinases, 90-kDa
ribosomal protein S6 kinase, 90kDa, polypeptide 3